Logo image of XCUR

EXICURE INC (XCUR) Stock Fundamental Analysis

USA - NASDAQ:XCUR - US30205M3097 - Common Stock

4.45 USD
-0.01 (-0.22%)
Last: 10/30/2025, 2:59:44 PM
Fundamental Rating

2

Taking everything into account, XCUR scores 2 out of 10 in our fundamental rating. XCUR was compared to 534 industry peers in the Biotechnology industry. While XCUR seems to be doing ok healthwise, there are quite some concerns on its profitability. XCUR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year XCUR has reported negative net income.
XCUR had a negative operating cash flow in the past year.
In the past 5 years XCUR always reported negative net income.
XCUR had a negative operating cash flow in each of the past 5 years.
XCUR Yearly Net Income VS EBIT VS OCF VS FCFXCUR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of XCUR (-42.07%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -88.94%, XCUR is in line with its industry, outperforming 49.44% of the companies in the same industry.
Industry RankSector Rank
ROA -42.07%
ROE -88.94%
ROIC N/A
ROA(3y)-73.86%
ROA(5y)-68.98%
ROE(3y)-239.53%
ROE(5y)-266.21%
ROIC(3y)N/A
ROIC(5y)N/A
XCUR Yearly ROA, ROE, ROICXCUR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XCUR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XCUR Yearly Profit, Operating, Gross MarginsXCUR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K -10K

5

2. Health

2.1 Basic Checks

XCUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
XCUR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for XCUR has been increased compared to 5 years ago.
XCUR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XCUR Yearly Shares OutstandingXCUR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
XCUR Yearly Total Debt VS Total AssetsXCUR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

XCUR has an Altman-Z score of -14.36. This is a bad value and indicates that XCUR is not financially healthy and even has some risk of bankruptcy.
XCUR's Altman-Z score of -14.36 is on the low side compared to the rest of the industry. XCUR is outperformed by 79.78% of its industry peers.
There is no outstanding debt for XCUR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.36
ROIC/WACCN/A
WACC8.63%
XCUR Yearly LT Debt VS Equity VS FCFXCUR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 1.89 indicates that XCUR should not have too much problems paying its short term obligations.
With a Current ratio value of 1.89, XCUR is not doing good in the industry: 77.34% of the companies in the same industry are doing better.
A Quick Ratio of 1.89 indicates that XCUR should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.89, XCUR is doing worse than 75.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.89
XCUR Yearly Current Assets VS Current LiabilitesXCUR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

0

3. Growth

3.1 Past

XCUR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.07%.
XCUR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
XCUR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -17.40% yearly.
EPS 1Y (TTM)-42.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.64%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-17.4%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XCUR Yearly Revenue VS EstimatesXCUR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2024 0 5M 10M 15M 20M 25M
XCUR Yearly EPS VS EstimatesXCUR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 -20 -40 -60 -80 -100

0

4. Valuation

4.1 Price/Earnings Ratio

XCUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XCUR Price Earnings VS Forward Price EarningsXCUR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XCUR Per share dataXCUR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

XCUR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

EXICURE INC

NASDAQ:XCUR (10/30/2025, 2:59:44 PM)

4.45

-0.01 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11
Earnings (Next)11-12 2025-11-12
Inst Owners12.88%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner Change0%
Market Cap28.12M
Revenue(TTM)N/A
Net Income(TTM)-7883000
Analysts43.33
Price TargetN/A
Short Float %1.33%
Short Ratio0.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.17
P/tB 16.17
EV/EBITDA N/A
EPS(TTM)-3.26
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS0
BVpS1.4
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.07%
ROE -88.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.86%
ROA(5y)-68.98%
ROE(3y)-239.53%
ROE(5y)-266.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.89
Altman-Z -14.36
F-Score4
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.64%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-17.4%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-39.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y74.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.44%
OCF growth 3YN/A
OCF growth 5YN/A

EXICURE INC / XCUR FAQ

Can you provide the ChartMill fundamental rating for EXICURE INC?

ChartMill assigns a fundamental rating of 2 / 10 to XCUR.


Can you provide the valuation status for EXICURE INC?

ChartMill assigns a valuation rating of 0 / 10 to EXICURE INC (XCUR). This can be considered as Overvalued.


Can you provide the profitability details for EXICURE INC?

EXICURE INC (XCUR) has a profitability rating of 1 / 10.


What is the financial health of EXICURE INC (XCUR) stock?

The financial health rating of EXICURE INC (XCUR) is 5 / 10.